Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
57°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
43.08
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirum Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Where Mirum Pharmaceuticals Stands With Analysts
August 21, 2023
Via
Benzinga
Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know
July 18, 2023
Via
Benzinga
Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday
July 18, 2023
B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02...
Via
Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
The Latest Analyst Ratings for Mirum Pharmaceuticals
June 15, 2023
Via
Benzinga
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
June 03, 2023
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...
Via
Talk Markets
Analyst Expectations for Mirum Pharmaceuticals's Future
May 22, 2023
Via
Benzinga
Mirum Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
April 06, 2023
Via
Benzinga
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 12, 2023
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...
Via
Benzinga
American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday
April 12, 2023
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed
March 10, 2023
Via
Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
March 09, 2023
Via
Benzinga
Earnings Preview: Mirum Pharmaceuticals
March 07, 2023
Via
Benzinga
Mirum Pharmaceuticals's Return On Capital Employed Insights
December 14, 2022
Via
Benzinga
Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease
December 13, 2022
Via
Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
March 11, 2023
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...
Via
Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
January 10, 2023
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...
Via
Benzinga
Robinhood, MicroStrategy And Other Big Losers From Wednesday
November 10, 2022
U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Earnings Scheduled For March 8, 2023
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
Where Mirum Pharmaceuticals Stands With Analysts
November 10, 2022
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:
Via
Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
November 10, 2022
Gainers
Via
Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
November 09, 2022
Gainers
Via
Benzinga
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
October 26, 2022
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
Via
Benzinga
Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration
October 25, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Upgrades
Via
Benzinga
'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks
August 30, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them....
Via
Benzinga
Looking Into Mirum Pharmaceuticals's Return On Capital Employed
August 23, 2022
According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of...
Via
Benzinga
Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered
August 10, 2022
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share....
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.